In Clinical Trials, Look to the East
Untapped and treatment naive patients in emerging countries such as Central and Eastern Europe offer pharmaceutical companies the opportunity to speed up clinical trials and avoid perhaps the largest cost in drug development: delay in reaching the market. CROs, too, see the EEC as the newest large growth opportunity.
You may also be interested in...
Just five weeks before the US election, a Medtech Insight analysis shows medical device companies are spending more on Democrat Joe Biden’s campaign than on Republican Donald Trump’s.
Denmark’s Orphazyme has raised more funds to market its lead product, the heat shock protein amplifier, arimoclomol, in the US and Europe, and to evaluate the compound for other lysosomal storage and neurodegenerative disorders.
Pacific Biosciences of California and Aziyo Biologics both acquire new finance chiefs; Illumina hires a new chief marketing officer; WishBone Medical president moves over to take helm at Electromedical Products International; and more.